Partnering opportunities - Core Therapeutic Areas

We are looking for high-value, truly differentiating first or best-in-class treatments in:

Focus on areas of high unmet need, build on strong mid/late-stage pipeline

Atherosclerosis

  • ASCVD prevention and treatment
  • Novel mechanisms beyond LDL-C, Lp(a), HTN, and inflammation.

Heart Failure/Atrial Fibrillation

  • Heart Failure with reduced or preserved ejection fraction
  • Safer anti-arrhythmic therapies for Afib
  • Cardiomyopathies, thrombosis, and hypertension

Metabolism/Obesity

  • Novel mechanisms that complement SoC
  • Better tolerability and weight loss maintenance

Nephrology

  • Chronic Kidney Disease (Stage 3b/4)
  • Glomerular diseases e.g. IgA Nephropathy (IgAN), Alport Syndrome
Avi Spier

Avi Spier

Contact

Strong foundation and expect 6 Ph3 readouts, >10 Ph2 readouts in next 5 years Dermatology

  • Atopic Dermatitis
  • Chronic Spontaneous Urticaria (CSU)
  • Hidradenitis Suppurativa
  • Lichen Planus
  • Vitiligo

Rheumatology

  • Lupus nephritis (LN)
  • Sjogren's disease
  • Spondyloarthropathies

Systemic Lupus Erythematosus (SLE)

Inflammatory Bowel Disease

  • Crohn's Disease
  • Ulcerative Colitis

Exploratory Areas

  • B cell reset
  • Food allergy
  • Rheumatoid Arthritis
Dominic Ehrismann portrait

Dominic Ehrismann

Contact

Focus on multiple sclerosis, neuromuscular and neurodegenerative diseases

Neurodegeneration

  • Parkinson’s Disease (PD)
  • Alzheimer’s Disease
  • Huntington’s Disease

Neuromuscular

  • Amyotrophic lateral sclerosis (ALS)
  • Larger neuro-muscular indications

Multiple Sclerosis & Immuno-Neurology

  • Multiple Sclerosis (MS)
  • Other neuroimmunology diseases (e.g., CIDP & MG)
Chris Adams

Christopher Adams

Contact

Focus areas on solid tumors, RLT and hematology

Solid Tumors

  • Breast cancers
  • Prostate cancers
  • Lung cancers
  • Colorectal and pancreatic cancers

 

Radioligand Therapy

  • Identify RLTs or PET imaging agents in solid tumor indications including novel isotopes, chelators, vectors, and targets

Hematology

  • Non-Hodgkin lymphoma (NHL)
  • Acute myeloid leukemia (AML) / Myelodysplastic syndrome (MDS)
  • Non-malignant hematology, Myeloproliferative Neoplasms (MPN)
Markus Werner

Markus Werner

Contact

Partnering opportunities - Platforms and AI

We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:

  • Artificial intelligence/Machine learning (AI/ML) approaches to accelerate discovery and synthesis of new molecular entities
  • Automated synthesis and profiling platforms
  • Novel cyclic peptide screening platforms
Avi Spier

Avi Spier

Contact

  • Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery.
  • Targeted delivery and selective tropism to key tissues/cell types
  • Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates
Gianfranco de Pascale

Gianfranco de Pascale

Contact

  • Novel T-cell-based therapy approaches
  • Approaches to reduce AAV immunogenicity
  • NextGen gene editing (non-viral)
  • Novel approaches for selective gene expression in target cells for GTx
Markus Werner

Markus Werner (Oncology)

Contact

 

Elizabeth Leshen

Elizabeth Leshen (Rare diseases and neuroscience)

Contact

  • Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types
  • Innovative siRNA chemistry platforms
  • In vivo/In vitro platforms to identify and validate siRNA targets
Gianfranco de Pascale

Gianfranco de Pascale

Contact

  • Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery
  • Explore various combination approaches which are synergistic with RLTs
  • Technologies to expand the therapeutic window of RLTs
Shona Whyte portrait

Shona Whyte

Contact

We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:

  • Enable deeper understanding of disease to identify novel therapeutic Targets
  • Power small and large molecule design and optimization
  • Increase predictive safety
  • Improve trial design and execution
Cynthia Hong

Cynthia Hong

Contact

Partnering opportunities - Other Areas

Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.

Guy Greiveldinger

Guy Greiveldinger

Contact

 

Frank Dieterle

Frank Dieterle

Contact

Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.

Charles Bailey

Charles Bailey

Contact

Discover more